"Designing Growth Strategies is in our DNA"

U.S. Nuclear Medicine Market Size, Share, Analysis, By Type (Diagnostic Radiopharmaceuticals {PET Radiopharmaceuticals [FDG-PET/18F, 68Ga, 68Cu, 11C, and Others] and SPECT Radiopharmaceuticals [Technetium-99m, Iodine-123, Xenon-133, Thallium-201, and Others]}, and Therapeutic Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End-user (Hospitals & Clinics, Diagnostic Centers, and Others), and Country Forecast, 2024-2032

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI109233

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. New Product Launches, Key Players
    2. Key Industry Developments - Mergers, Acquisitions, and Partnerships
    3. Overview of Regulatory Scenario
    4. Impact of Covid-19 on the Market
    5. Pipeline Analysis
  5. U.S. Nuclear Medicine Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type
      1. Diagnostic Radiopharmaceuticals
        1. PET Radiopharmaceuticals
          1. FDG-PET/18F
          2. 68Ga
          3. 68Cu
          4. 11C
          5. Others
        2. SPECT Radiopharmaceuticals
          1. Technetium-99m
          2. Iodine-123
          3. Xenon-133
          4. Thallium-201
          5. Others
      2. Therapeutic Radiopharmaceuticals
    2. Market Analysis, Insights and Forecast – By Application
      1. Neurology
      2. Cardiology
      3. Oncology
      4. Others
    3. Market Analysis, Insights and Forecast – By End-user
      1. Hospitals & Clinics
      2. Diagnostic Centers
      3. Others
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Lantheus
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Cardinal Health
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Bracco
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. GE HealthCare (General Electric Company)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. CURIUM
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. Bayer AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. RLS, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      8. Advanced Accelerator Applications (Novartis AG)
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      9. Nordion (Canada) Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      10. Jubilant Pharma Limited
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
Read Less

Table 01: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, By Type, 2019–2032

Table 02: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, Diagnostic Radiopharmaceuticals, 2019–2032

Table 03: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, PET Radiopharmaceuticals, 2019–2032

Table 04: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, SPECT Radiopharmaceuticals, 2019–2032

Table 05: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, By Application, 2019–2032

Table 06: U.S. Nuclear Medicine Market Revenue (USD billion) Forecast, By End-user, 2019–2032

Figure 01: U.S. Nuclear Medicine Market Revenue Breakdown (USD billion, %), By Type, 2024 & 2032

Figure 02: U.S. Nuclear Medicine Market Value Share (%), By Type, 2024 & 2032

Figure 03: U.S. Nuclear Medicine Market Value Share (%), By Application, 2024 & 2032

Figure 04: U.S. Nuclear Medicine Market Value Share (%), By End-user, 2024 & 2032

Figure 05: U.S. Nuclear Medicine Market Share Analysis (%), By Company, 2023

U.S. Nuclear Medicine Market Size, Share and Global Industry Trend Forecast till 2032
  • 2019-2032
  • 2023
  • 2019-2022
  • 70
Consulting Services
    How will you benefit from our consulting services ?